Compare LFUS & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LFUS | HALO |
|---|---|---|
| Founded | 1927 | 1998 |
| Country | United States | United States |
| Employees | 17000 | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 12.0B |
| IPO Year | 1996 | 2001 |
| Metric | LFUS | HALO |
|---|---|---|
| Price | $423.11 | $112.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $366.67 | $78.64 |
| AVG Volume (30 Days) | 160.8K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.96 | ★ 3.11 |
| Revenue | ★ $757,853,000.00 | $151,862,000.00 |
| Revenue This Year | $14.65 | $28.24 |
| Revenue Next Year | $6.98 | $12.56 |
| P/E Ratio | $141.51 | ★ $37.02 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $233.36 | $61.23 |
| 52 Week High | $500.57 | $115.18 |
| Indicator | LFUS | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 49.70 | N/A |
| Support Level | $389.23 | N/A |
| Resistance Level | $428.88 | N/A |
| Average True Range (ATR) | 11.70 | 0.00 |
| MACD | 1.29 | 0.00 |
| Stochastic Oscillator | 57.12 | 0.00 |
Littelfuse is a supplier of circuit protection products (such as fuses and relays) for the transportation, industrial, telecommunications, and consumer electronics end markets. Littelfuse also holds a minority power semiconductor business, primarily serving high-voltage industrial applications. Littelfuse sells globally across both distribution and direct channels, and organizes its business into the three segments of electronics, transportation, and industrial. Littelfuse is a serial acquirer of smaller, bolt-on adjacent firms.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.